K103818

# 510(k) Summary

Submitted By:

Submitter: Ventana Medical Systems, Inc. Contact: George De La Rosa Date Prepared: November 15, 2011

This summary of $5 1 0 ( k )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: K103818

<table><tr><td colspan="1" rowspan="1">EY</td><td></td></tr><tr><td colspan="1" rowspan="4">Device Name</td><td colspan="1" rowspan="1">CONFIRM anti-Progesterone Receptor (1E2) Rabbit Monoclonal Primary Antibody</td></tr><tr><td colspan="1" rowspan="1">Antibody for aid in the detection of progesterone receptor (PGR)Common name:antigen in histological tissue sections</td></tr><tr><td colspan="1" rowspan="1">Classification:     Class II Non-exempt</td></tr><tr><td colspan="1" rowspan="1">Product Code:     MXZ</td></tr><tr><td colspan="1" rowspan="2">PredicateDevice</td><td colspan="1" rowspan="1">CONFIRM anti-Progesterone Receptor (1E2) Rabbit Monoclonal Primary Antibody issubstantially equivalent to DAKO North America's commercially available MonoclonalMouse Anti Human Progesterone Receptor, Clone PGR 636</td></tr><tr><td colspan="1" rowspan="1">K020023</td></tr><tr><td colspan="1" rowspan="1">DeviceDescription</td><td colspan="1" rowspan="1">Ventana's CONFIRM anti-Progesterone Receptor (1E2) Rabbit Monoclonal PrimaryAntibody specifically binds to progesterone receptor antigen located in the nuclearregion of a variety of normal and neoplastic tissues. The antibody is diluted in 0.05 MTris-HCl with 2% carrier protein, and 0.1% ProClin 300, a preservative. There is trace(0.2%) fetal calf serum of U.S. origin from the stock solution. Total proteinconcentration of the reagent is approximately 10 mg/mL. Specific antibodyconcentration is approximately 1 Âµg/mL. CONFIRM anti-PR (1E2) is a rabbitmonoclonal antibody produced as a cell culture supernatant.</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">This antibody is intended for in vitro diagnostic (IVD) use.CONFIRM anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal (IgG)Primary Antibody is intended for laboratory use for the qualitative detection ofprogesterone receptor (PR) antigen in sections of formalin-fixed, paraffin-embedded tissue on a VENTANA automated slide stainer with VENTANAdetection kits and ancillary reagents. CONFIRM anti-PR (1E2) is directedagainst an epitope present on human progesterone receptor protein located inthe nucleus of PR positive normal and neoplastic cells. CONFIRM anti-PR(1E2) is indicated as an aid in the management, prognosis, and prediction ofhormone therapy for breast carcinoma.This product should be interpreted by a qualified pathologist in conjunctionwith histological examination, relevant clinical information, and proper controls.Prescription use only.</td></tr><tr><td colspan="1" rowspan="1">Summary ofthe new andpredicatedevices</td><td colspan="1" rowspan="1">CONFIRM anti-PR (1E2) is a rabbit monoclonal antibody that recognizes the A and Bforms of human progesterone receptor. The immunogen was developed from asynthetic peptide identified as an area of potential high antigenicity common toprogesterone receptor A and B forms. The peptide was synthesized and covalentlybound to keyhole limpet hemocyanin to further increase antigenicity. CONFIRM anti-PR (1E2) has been shown to react with 60 kD, 87 kD and 110 kD proteins from T47D</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">cells via Western blotting. The protein sizes are in agreement with the predictedmolecular weight of progesterone receptor forms A, B and C.12Dako FLEX Monoclonal Mouse Anti-Human Progesterone Receptor Clone PgR 636consists of a mouse anti-human monoclonal antibody produced as a tissue culturesupernatant is used in the qualitative detection of human progesterone receptor intissue sections of human breast cancer by immunohistochemistry.Both products specifically bind to progesterone receptor proteins located in the nucleiof cells, and these products require similar detection chemistry principles forvisualization of the product, and both aid in the prognosis of breast carcinoma.</td></tr><tr><td colspan="1" rowspan="1">Non-clinicalperformancedata</td><td colspan="1" rowspan="1">Distribution of progesterone receptor throughout normal tissue has been reported in avariety of studies. The required panel of normal tissues was tested with this antibodyas specified in the 6/3/98 final version of Guidance for Submissions ofImmunohistochemistry Applications to the FDA. All tissues were formalin fixed andparaffin embedded.Non-clinical performance testing has been conducted to demonstrate performancecharacteristics of CONFIRM anti-PR (1E2). Results of tissue-specificity and precisiontesting are noted in the product package insert.</td></tr><tr><td colspan="1" rowspan="1">Clinicalperformancedata</td><td colspan="1" rowspan="1">A randomized, multi-site, multi-reader study was conducted to compare the stainingperformance of the CONFIRM anti-PR (1E2) on the BenchMark ULTRA instrumentand on the BenchMark XT instrument to that of the Dako FLEX Monoclonal MouseAnti-Human Progesterone Receptor Clone PgR 636 Ready-To-Use (FLEX anti-PgR(636)) on the Dako Autostainer Plus.Approximately 120 negative and 216 positive cases of breast cancer, representing theclinical range of the assay, were randomly assigned to three study sites such thateach site received an equal number of cases and each site received casesrepresenting each clinical assessment category.For CONFIRM anti-PR (1E2) staining on the BenchMark ULTRA instrument comparedto the FLEX anti-PgR (636) on the Dako Autostainer Plus, the positive, negative, andoverall agreement rates (pooled across all testing sites) were greater than 85%. ForCONFIRM anti-PR (1E2) staining on the BenchMark XT instrument compared to theFLEX anti-PgR (636) on the Dako Autostainer Plus, the positive, negative, and overallagreement rates were all greater than 85%. For CONFIRM anti-PR (1E2) staining onthe BenchMark ULTRA instrument compared to the CONFIRM anti-PR (1E2) stainingon the BenchMark XT instrument, the positive, negative, and overall agreement rateswere all greater than 85%.</td></tr></table>

Ventana Medical Systems, Inc. c/o Mr. George De La Rosa Manager, Regulatory Affairs 1910 E. Innovation Park Drive Tucson, AZ 85755

# NOV 16 2011

Re: k103818 Trade/Device Name: CONFIRM anti-Progesterone Receptor (1E2) Rabbit Monoclonal Primary Antibody Regulation Number: 21 CFR $\$ 864.1860$ Regulation Name: Immunohistochemistry reagents and kits Regulatory Class: Class II Product Codes: MXZ Dated: October 26, 2011 Received: October 27, 2011

Dear Mr. De La Rosa:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of

Page 2 - Mr. George De La Rosa

substantial equivalence of your device to a legally marketed predicate device results in a   
classification for your device and thus, permits your device to procced to the market.   
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,mana M chan

Maria M. Chan, Ph.D.   
Director   
Division of Immunology and Hematology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

# Indications for Use

510(k) Number: K103818

Device Name: CONFiRM Anti-Progesterone Receptor (1E2) Rabbit Monoclonal Primary Antibody

This antibody is intended for in vitro diagnostic (IVD)use.

CONFIRM anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal (IgG) Primary Antibody is intended for laboratory use for the qualitative detection of progesterone receptor (PR) antigen in sections of formalin-fixed, paraffin-embedded tissue on a VENTANA automated slide stainer with VENTANA detection kits and ancillary reagents. CONFIRM anti-PR (1E2) is directed against an epitope present on human progesterone receptor protein located in the nucleus of PR positive normal and neoplastic cells. CONFiRM anti-PR (E) is indicated as an aid in the management, prognosis, and prediction of hormone therapy for breast carcinoma.

This product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.

Prescription use only.

(ription U e ) AND/OR Over-The-Countr use)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/94e84708a4512a0a026cea530d62dfdf61cbea10a21a63883fab09e45d2fd417.jpg)

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(k) K103818